Drug Trial Radar · NCT07808905
Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Oct 31, 2029
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- ENCellIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Sarcopenia
Conditions
- Sarcopenia
Interventions
EN001Drug
\- Phase1-Cohort 1: EN001 Low dose administered intravenously (IV) 3 times at 4 week intervals.
EN001Drug
-Phase2-Cohort 2 : EN001 Medium dose administered intravenously (IV) 3times at 4 week intervals.
EN001Drug
-Phase1-Cohort 3 : EN001 High dose administered intravenously (IV) 3times at 4 week intervals.
EN001Drug
-Phase2-Cohort 1 : EN001 Low dose(Recommended Phase 2 Dose\[RP2D\] of EN001) administered intravenously (IV) 3times at 4 week intervals.
EN001Drug
-Phase2-Cohort2 : EN001 High dose(Recommended Phase 2 Dose\[RP2D\] of EN001) administered intravenously (IV) 3times at 4 week intervals.
EN001 PlaceboDrug
-Phase2-Placebo : EN001 Placebo administered intravenously (IV) 3times at 4 week intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Phase1] Dose limiting toxicity (DLT) and adverse drug reactions related to discontinuation of investigational product administrationTime frame: Up to 12 weeks
- [Phase2] Change from baseline in the SPPB(Short Physical Performance Battery) at Week 24Time frame: at Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.